Strata Skin Sciences Outlines Growth Initiatives for 2025

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potentialThe latest announcement is out from Strata Skin Sciences ( (SSKN) ). STRATA Skin Sciences posted a new investor presentation outlining its strategic initiatives for expansion and growth in December 2025. Key highlights include advancements in reimbursement policies starting January 2027, which will significantly expand the addressable patient market, and a legal victory against LaserOptek for false advertising, reducing competition and potentially strengthening its financial position. These developments, alongside a cash-flow-positive 2024 and plans to leverage enhanced technologies and market strategies, position the company for increased market share and stakeholder value. The most recent analyst rating on (SSKN) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Strata Skin Sciences stock, see the SSKN Stock Forecast page. Spark’s Take on SSKN Stock According to Spark, TipRanks’ AI Analyst, SSKN is a Neutral. The overall stock score is primarily impacted by the company’s weak financial performance and bearish technical indicators. While there are some positive developments from the earnings call, such as market expansion and litigation success, these are overshadowed by significant revenue declines and ongoing financial challenges. To see Spark’s full report on SSKN stock, click here. More about Strata Skin Sciences STRATA Skin Sciences, Inc. operates in the therapeutic and aesthetic dermatology industry, focusing on advanced laser and light-based devices. Their products include the XTRAC excimer laser for treating autoimmune diseases like psoriasis and vitiligo, the TheraClearX system for acne treatment, and the VTRAC Excimer Lamp System. They provide solutions for recurring revenue driven by in-office procedures, reimbursed by Medicare and private payers. Average Trading Volume: 4,098,750 Technical Sentiment Signal: Sell Current Market Cap: $7.83M